On July 13, 2025, Becton, Dickinson and Company announced a significant agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a transaction worth approximately $4 billion, where BD shareholders will own 39.2% of Waters post-merger. This strategic move includes a cash distribution and a spin-off of the Biosciences and Diagnostic Solutions segment before merging with Waters.